Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07575399 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
A Phase 3 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07575399 is a Phase 3 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 300 participants.
The verdict
NCT07575399, a Phase 3 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Interventions
- DRUG Maridebart Cafraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07575399
The ClinicalTrials.gov registry entry for NCT07575399 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maridebart Cafraglutide is the first listed.
NCT07575399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07575399 about?
NCT07575399 is a clinical study titled "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)". Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
What is the current status of trial NCT07575399?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-05-11. Estimated completion is 2028-02-28.
What interventions are being tested in trial NCT07575399?
The interventions under investigation include: Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07575399?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.